Brought to you by 
Antisoma licenses CRC's vascular targeting agent
26 Feb 2002
Executive Summary
Antisoma (cancer treatments) licensed vascular targeting agent DMXAA from Cancer Research Ventures, the tech transfer arm of the Cancer Research Campaign. It paid $1.02mm (UK700k) up front in cash and stock, and will potentially provide CRV with milestones and royalties.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Antisoma licenses CRC's vascular targeting agent
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice